Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS; PRACTICAL consortium. Went M, et al. Among authors: bertsch u. Nat Commun. 2018 Sep 13;9(1):3707. doi: 10.1038/s41467-018-04989-w. Nat Commun. 2018. PMID: 30213928 Free PMC article.
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Krämer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H. Hose D, et al. Among authors: bertsch u. Blood. 2009 Apr 30;113(18):4331-40. doi: 10.1182/blood-2008-09-178350. Epub 2009 Jan 26. Blood. 2009. PMID: 19171872 Free PMC article.
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D. Seckinger A, et al. Among authors: bertsch u. Oncogene. 2009 Nov 5;28(44):3866-79. doi: 10.1038/onc.2009.257. Epub 2009 Aug 31. Oncogene. 2009. PMID: 19718049 Free PMC article.
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H. Neben K, et al. Among authors: bertsch u. Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10. Haematologica. 2010. PMID: 20220069 Free PMC article.
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P. Broyl A, et al. Among authors: bertsch u. Blood. 2010 Oct 7;116(14):2543-53. doi: 10.1182/blood-2009-12-261032. Epub 2010 Jun 23. Blood. 2010. PMID: 20574050 Free article.
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Broyl A, et al. Among authors: bertsch u. Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21. Lancet Oncol. 2010. PMID: 20864405 Clinical Trial.
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H. Hose D, et al. Among authors: bertsch u. Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296. Epub 2010 Sep 30. Haematologica. 2011. PMID: 20884712 Free PMC article.
Timing of the high-dose therapy in the area of new drugs.
Schmitt S, Bertsch U, Hose D, Goldschmidt H. Schmitt S, et al. Among authors: bertsch u. Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:90-4. doi: 10.2298/sarh11s2090s. Srp Arh Celok Lek. 2011. PMID: 22352189 Free article.
105 results